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Background and Aim. Depression is a social problem with high economic burden in the society. Finding an effective agent with high
efficacy and few side effects is therefore needed. Involvement of neuroimmune response as well as nitric oxide (NO) has been
determined in the pathophysiology of depression. Limonene is a terpene with various pharmacological properties. Thus, we
aimed to evaluate antidepressant-like effect of limonene on a mouse model of maternal separation (MS) focusing on
neuroinflammation and NO level in the hippocampus. Methods. Mice were randomly divided into experimental groups as
follows: the control group received normal saline and MS groups received normal saline, limonene (10 and 20mg/kg), L-NAME
(10mg/kg), L-arginine (L-arg) (75mg/kg), limonene (10mg/kg) plus L-NAME, and limonene (20mg/kg) plus L-arg. Behavioral
tests including the forced swimming test (FST), open field test (OFT), and splash test were performed. Finally, serum and
hippocampal nitrite levels as well as the expression of inflammatory genes (IL-1β and TNF-α) in the hippocampus were
measured. Results. We showed that MS caused depressive-like behavior. Treatment of MS mice with limonene reduced the
duration of immobility time in FST and increases the grooming activity time in the splash test. Limonene also reduces serum
and brain nitrite levels and reduces the expression of IL-1β and TNF-α in the hippocampus. We found that L-NAME
potentiated the effects of a subeffective dose of limonene. Conclusion. We concluded that the antidepressant-like effects of
limonene are probably mediated through inhibition of neuroinflammation and attenuation of nitrite levels in the hippocampus.
1. Introduction
Depression is one of the most common psychiatric disorders
that is a common and important cause of disability in the
world [1, 2]. According to the World Health Organization,
about 264 million people worldwide suffer from depression
[3]. Maternal separation (MS) is an approved model designed
to induce stress during the early life in rodents [4]. MS is
defined as the lack of care, short-term care, or repeated sepa-
ration from mothers during early life, which undesirably
affect the development of the brain. Infants under MS stress
are prone to development of anxiety, depression, memory
loss, and neurological disorders in adulthood [4].
It has been determined that there is an interrelationship
between neural inflammation and depression. Evidence sug-
gests that some inflammatory mediators, such as tumor
necrosis factor alpha (TNF-α) and interleukin-1beta (IL-
1β), are involved in the development of depressive disorders
[5, 6]. Furthermore, previous studies have shown that oxida-
tive and nitrosative stresses usually play a key role in the
pathophysiology of depression by activating the immune
response [7]. In this regard, it has been well determined that
nitrite oxide (NO) acts as an activator of neuroinflammatory
response [8]. Studies have also shown that the levels of
inflammatory markers are increased in people with depres-
sive symptoms [9]. It seems that the association between
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inflammatory reactions with depression led to a lack of full
response to current antidepressants which commonly affect
serotonergic neurotransmission [10]. Considering the fact
of the growing prevalence of depression, there is a demand-
ing need to introduce new effective agents with favorable
and potent pharmacological possessions as well as low side
effects.
Limonene is one of the most common terpenes (C10H16)
in nature and is a major component of citrus extracts such as
lemon, orange, tangerine, and grapefruit [11]. It has been
shown that D-limonene reduced oxidative stress and inflam-
matory responses [12, 13]. Evidences have demonstrated that
limonene through the effect on the parasympathetic system
and central neurotransmitter activity possessed antidepres-
sant effect [14]. However, the exact and complete mecha-
nisms involved in the antidepressant effect of limonene
have not yet been fully identified.
Considering the role of neuroinflammation and NO in
the pathophysiology of depression as well as the reported
neuroprotective effects for limonene, this study was per-
formed to evaluate the possible reducing effects of hippo-
campal neuroinflammation and nitrite level on the
antidepressant-like effect of limonene in a mouse model
of MS stress.
2. Material and Methods
2.1. Ethical Approval. All procedures were carried out in
accordance with the regulations of the University and the
Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health (Ethics code: IR.SKUMS.-
REC.1397.129) and Guide for the Care and Use of Laboratory
Animals (8th edition, National Academies Press). Full efforts
were made to reduce the use of animals and to advance their
welfare.
2.2. Maternal Separation. Pregnant NMRI mice (first-day
pregnancies) were purchased from the Pasteur laboratory
(Pasteur Institute, Tehran, Iran) and kept under standard
laboratory conditions (12-hour periods of darkness and light
and at 22 ± 2°C and free access to water and food). The birth-
day was considered the postnatal day ðPNDÞ = 0. Pups in
PND = 2 up to PND = 14 were separated from their mothers
for 3 constant hours daily [15, 16]. At the end of PND = 14,
the pups returned to their mother’s cages and were kept
intact until day 21. From day 21, mice were isolated from
their mother and were kept in cages in groups of 4 until
PND 60 (22–30 g weight). Control mice were kept in the
mother cage from PND 0 to PND 21 without manipulation
and were then kept in cages in groups of 4 from PND 21 to
PND 60.
2.3. Drugs. The drugs used in this study were as follows: (1)
limonene, (2) L-NAME (a nonselective nitric oxide synthase
or NOS inhibitor), and (3) L-arginine (a NO precursor). All
agents were bought from Sigma, St. Louis, MO, USA. Drugs
were dissolved in 0.9% physiological saline and injected as a
single dose via the intraperitoneal route (i.p.) with a volume
of 5ml/kg body weight.
2.4. Animals and Study Design. 64 male NMRI mice were
randomly divided into 8 groups (n = 8). Group 1 was the
control mice which received normal saline. Groups 2-8 were
MS mice which received normal saline, limonene at doses of
10 and 20mg/kg, L-NAME at a dose of 10mg/kg, L-arginine
(l-arg) at a dose of 75mg/kg, an ineffective dose of limonene
plus L-NAME, and an effective dose of limonene plus L-argi-
nine, respectively. Mice were treated with L-arg (30min),
L-NAME (45min), and limonene (60min) prior to the
behavioral tests. The dose and time of drug administra-
tions were chosen according to the previous studies [17–
19] as well as our pilot studies. Each mouse was used only
for one test (the same mice were used for the FST and the
OFT, and different sets of mice were used for the splash test).
In order to prevent the effects of manipulation by different
experimenters on animals, all experiments were conducted
by a single experimenter. Each experimental group contained
8 mice for behavioral tests and 4 samples for molecular
assessments (gene expression and nitrite level). The sche-
matic of the study design is shown in Figure 1.
2.5. Forced Swimming Test (FST). In this experiment, the
immobility time of the mice was recorded as a reflection of
depressive-like behavior. To do this, a glass container
(25 × 12 × 15 cm) filled with 25°C water and mouse was
placed gently in the water from a height of 20 cm. Disruption
of mouse movements was considered immobility. The test
time was 6 minutes; the first 2 minutes was considered to
match the animal with the current conditions, and the immo-
bility time was measured for the next 4 minutes [20].
2.6. Open Field Test (OFT). The OFT was performed to eval-
uate the locomotor activity following treatments. The OFT
was done immediately before the FST to consider ambulatory
behavior as well as to confirm that adjustments which occur
in motor activity did not affect the immobility time in the
FST. The OFT device is a white Plexiglas with dimensions
of 30 × 50 × 50 cm. Each mouse was gently placed in the mid-
dle of the device. Its movements were recorded by a camera
for 5 minutes and evaluated by Ethovision software version
8. In the OFT, the horizontal (distance moved, number of
crossing by 4 feet from each square) and vertical (number
of rearings) activities were measured [21]. The apparatus
was cleaned with 70% ethanol after the experiment with each
mouse.
2.7. Splash Test. The splash test was used to examine personal
care and motivational problems in mice. To do this, a 10%
sucrose solution was sprayed on the dorsal coat of the mouse,
and its behavior was filmed for 5 minutes. In this test, self-
cleaning activities including nose/face cleaning, head wash-
ing, and body grooming were measured [22].
2.8. Nitrite Assay. The nitrite level as a stable NO product was
measured in the hippocampus and serum samples. In brief,
mice were sacrificed under anesthesia using diethyl ether,
and the hippocampus was dissected on the ice-cold surface
and directly placed into liquid nitrogen. Hippocampus
homogenates were prepared, and nitrite concentrations were
measured using a colorimetric assay based on the Griess
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reaction [23]. Briefly, each well was loaded with 100μl sam-
ples and mixed with 100μl Griess reagent. The absorbance
was measured at 540 nm in an automated plate reader, after
ten-minute incubation at room temperature. The level of
nitrite was determined by reference to a standard curve of
sodium nitrite (Sigma, USA) and normalized to the weight
of each sample.
2.9. The Expression of Inflammatory Genes. At the end of the
experiment, the mice were sacrificed under anesthesia using
diethyl ether, and the hippocampus was removed, and the
expression of IL-1β and TNF-α genes was assessed by real-
time PCR. The reaction for each gene was tripled and
repeated twice. The required specific primers were designed
using Primer 3 software version 0.4.0, and the H2afz gene
was considered a normalizer; the rate of change in expression
of the desired genes was compared with the control group.
Finally, the data were calculated using the PFAFFL formula.
The primer sequences are listed in Table 1.
2.10. Data Analysis. The data were analyzed using SPSS soft-
ware. One-way ANOVA followed by Tukey’s post hoc test
was used to determine significant differences among groups.
Data were recorded as the mean ± S:E:M:, and P < 0:05 was
considered statistically significant.
3. Results
3.1. Immobility Time in the FST. The results showed that MS
significantly increased the immobility time in the FST
(P < 0:001, Figure 2). The immobility time in the MS groups
that received limonene at a dose of 20mg/kg and L-NAME at
a dose of 10mg/kg significantly lowered than that of the
saline-treated MS group (P < 0:001). Concomitant adminis-
tration of limonene plus L-NAME to the MS mice signifi-
cantly reduced the duration of immobility compared to the
counterpart receiving a subeffective dose of limonene
(10mg/kg) alone (P < 0:001).
3.2. Locomotor Activity in the OFT. The results showed that
the horizontal activity (Figure 3(a)) in the MS group was sig-
nificantly lower than that of the control group (P < 0:001).
The administration of limonene at doses of 10 and 20mg/kg
significantly increased the horizontal activity compared to
the saline-treated MS group (P < 0:05).
Also, according to Figure 3(b), the vertical activity in
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Figure 1: Schematic of the study design.
Table 1: Primer sequences used in PCR amplification.































































Figure 2: Duration of immobility in the forced swimming test.
Values are presented as the mean ± S:E:M: from 8 animals and
were analyzed by one-way ANOVA followed by Tukey’s post hoc
test. ∗∗∗P < 0:001 compared to the control group. ###P < 0:001
compared to the MS group. @@@P < 0:001 compared to the MS
group receiving limonene at a dose of 10mg/kg. MS: maternal
separation; Lim: limonene; L-arg: L-arginine.
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group (P < 0:001). Administration of limonene at doses of
10 and 20mg/kg significantly increased vertical activity
compared to the saline-treated counterpart (P < 0:001).
Furthermore, injection of L-NAME and L-arg significantly
increased the vertical activity compared to the MS counter-
part (P < 0:01). Coadministration of limonene at the effec-
tive dose (20mg/kg) plus L-arg significantly increased the
vertical activity compared to the group that received the
effective dose of limonene alone (P < 0:001).
3.3. Grooming Activity Time in the Splash Test. Based on
the results shown in Figure 4, the duration of grooming
activity in the MS group is significantly lower than that
of the control group (P < 0:001). Administration of limo-
nene at a dose of 20mg/kg significantly increased groom-
ing activity compared to the saline-treated MS group
(P < 0:05). Also, administration of L-arg to the MS mice
significantly increased the duration of grooming activity
compared to the saline-treated MS group (P < 0:05). We
found that L-NAME significantly increased the grooming
activity time compared to the saline-treated MS group
(P < 0:001). Coadministration of L-NAME plus a subeffec-
tive dose of limonene (10mg/kg) significantly increased
the duration of grooming activity compared to the MS
group that received a subeffective dose of limonene alone
(P < 0:001).
3.4. The Brain and Serum Nitrite Levels. Based on our results
(Figure 5(a)), MS significantly increased the nitrite levels in
the serum compared to the control group (P < 0:001).
Administration of limonene at doses of 10 and 20mg/kg sig-
nificantly reduced the serum nitrite levels compared to the
saline-treated MS group (P < 0:001). Also, administration
of L-arg significantly reduced the serum nitrite levels com-
pared to the MS group treated with saline (P < 0:001).
Figure 5(b) shows that MS significantly increased the
brain nitrite levels compared to the control group
(P < 0:001). The results showed that administration of limo-























































































































Figure 3: The locomotor activity in the OFT. (a) Horizontal activity and (b) vertical activity. Values are presented as themean ± S:E:M: from
8 animals and were analyzed by one-way ANOVA followed by Tukey’s post hoc test. ∗∗∗P < 0:001 compared to the control group. #P < 0:05,
##P < 0:01, and ###P < 0:001 compared to theMS group. $$$P < 0:001 compared to the group that received limonene at a dose of 20mg/kg. MS:
































































Figure 4: Grooming activity duration in the splash test. Values are
presented as the mean ± S:E:M: from 8 animals and were analyzed
by one-way ANOVA followed by Tukey’s post hoc test. ∗∗∗P <
0:001 compared to the control group. #P<0.05 and ###P < 0:001
compared to the MS group. @@@P < 0:001 compared to the group
that received limonene at a dose of 10mg/kg. MS: maternal
separation; Lim: limonene; L-arg: L-arginine.
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reduced the brain nitrite levels compared to the saline-
treated MS mice (P < 0:001 and P < 0:05, respectively).
Coadministration of limonene at an effective dose of
20mg/kg plus L-arg significantly increased the brain nitrite
levels compared to the group that received an effective dose
of limonene alone (P < 0:05).
3.5. The Expression Inflammatory Genes in the Hippocampus.
As shown in Figure 6(a), the expression of Il-1β in the hippo-
campus of MS mice significantly increased compared to the
control group (P < 0:001). Administration of limonene at a
dose of 20mg/kg resulted in a significant reduction in Il-1β













































































































Figure 5: Nitrite levels in the brain and serum samples. Values are presented as themean ± S:E:M: from 4 samples and were analyzed by one-
way ANOVA followed by Tukey’s post hoc test. ∗∗∗P < 0:001 compared to the control group. #P < 0:05 and ###P < 0:001 compared to the MS





































































































































Figure 6: The expression of inflammatory genes in the hippocampus. (a) Il-1β and (b) Tnf-α. Values are presented as themean ± S:E:M: from
4 samples and were analyzed by one-way ANOVA followed by Tukey’s post hoc test. ∗∗P < 0:01 and ∗∗∗P < 0:001 compared to the control
group. #P < 0:05 and ##P < 0:01 compared to the MS group. @P < 0:05 compared to the group that received limonene (10mg/kg). MS:
maternal separation; Lim: limonene; L-arg: L-arginine.
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(P < 0:05). L-NAME significantly reduced the expression of
Il-1β compared to the MS counterpart (P < 0:01). Coadmin-
istration of the subeffective dose of limonene (10mg/kg) plus
L-NAME significantly reduced the expression of Il-1β com-
pared to the group that received the subeffective dose of lim-
onene alone (P < 0:05).
The results (Figure 6(b)) showed that MS significantly
increased the expression of Tnf-α gene compared to the
control group (P < 0:01). Limonene at a dose of 20mg/kg
significantly decreased the expression of the Tnf-α gene
compared to the MS counterpart (P < 0:01). Also, adminis-
tration of L-NAME significantly reduced the expression of
Tnf-α gene compared to the saline-treated MS group
(P < 0:05). The results showed that coadministration of
the subeffective dose of limonene (10mg/kg) plus L-
NAME significantly decreased the expression of Tnf-α
compared to the group that received the subeffective dose
of limonene alone (P < 0:05).
4. Discussion
Our findings showed that maternal separation caused
depressive-like behavior in mice. Limonene exerted
antidepressant-like effects on MS mice. We observed that
MS led to an increase in nitrite levels as well as overexpres-
sion of genes relevant to neuroinflammation. The results
showed that limonene reduced the neuroinflammatory
response and also reduced nitrite levels in the hippocampus.
Furthermore, coinjections of the subeffective dose of limo-
nene with the subeffective dose of L-NAME significantly
potentiated the antidepressant-like effect of the subeffective
dose of limonene. In addition, coinjection of the effective
dose of limonene with the effective dose of L-arg attenuated
the antidepressant effect of the effective dose of limonene.
Marais et al. showed that the MS, by changing the levels
of corticosteroids and neurotrophin in the hippocampus,
increases the risk of depressive-like behaviors in the FST fol-
lowing chronic stress [24]. Ample evidence showed that MS
increased the duration of immobility in the FST and reduced
the grooming activity time in the splash test [25]. Tchenio
et al. showed that MS has long-term effects on brain and
behavior development and led to the development of depres-
sion in adulthood [26]. Our findings determined that the MS
causes depressive-like behaviors in the FST and splash test in
mice. In this way, the immobility time in MS mice in the FST
test is increased and the time of self-care and self-cleaning is
significantly reduced in the splash test. In addition, we per-
formed the OFT to approve that locomotor activity subse-
quent to treatments does not affect the FST results, and the
immobility of animals in the FST is not associated with their
hypolocomotion [27]. In the other word, OFT was performed
directly before the FST to measure ambulatory behavior and
approve that inconsistencies which happen in motor activity
did not affect the immobility time in the FST.
d’Alessio et al. showed that D-limonene has significant
antistress and antiaggression effects [14]. Zhang et al. showed
that inhaling limonene significantly reduced depressive-like
behaviors. They demonstrated that alterations in neuroendo-
crine, neurotrophic, and monoaminergic systems have been
involved in the antidepressant-like effects of limonene [28].
Our study, along with other studies, showed that treatment
of MS mice with limonene significantly reduced the duration
of immobility in the FST and increased the grooming activity
time in the splash test indicating antidepressive-like proper-
ties of this agent.
Ludka et al. showed that drugs that reduce NO levels have
possessed antidepressant effects on major depressive disorder
[29]. Previously, it had been thought that antidepressants
only affected neurotransmitters [30]. However, there are evi-
dences showing that some commonly prescribed drugs may
exert their effects via normalizing the level of NO [31]. About
changes in NO levels in mice exposed to chronic stress, it has
been determined that the plasma level of NO was clearly
increased [32]. Our study, along with other studies, showed
that MS increased nitrite levels in serum and the brain. Also,
treatment of MS mice with limonene significantly reduced
brain and serum nitrite levels. This finding suggests that this
mechanism is at least partially involved in the antidepressant
effect of limonene on MS mice.
In a study in 2019, it was found that people with severe
symptoms of depression have high levels of preinflammatory
cytokines [33]. It has been verified that the increasing levels
of inflammatory factors such as IL-1, IL-6, and TNF-α are
associated with depressive-like behaviors [34]. It has been
shown that MS increased the expression of IL-1β and TNF-
α genes in the hippocampus [35]. Studies have showed that
some agents effectively mitigating depressive-like behaviors
significantly reduced the expression of genes relevant to neu-
roimmune response in the hippocampus [36, 37]. Studies
have shown that limonene reduced the inflammatory
response and decreased the levels of inflammatory cytokines
[14]. In our study, MS increased the expression of IL-1β and
TNF-α inflammatory genes in the hippocampus, indicating
that inflammatory response in the hippocampus was associ-
ated with depressive behaviors in MS mice. Also, limonene
significantly reduced the expression of these inflammatory
genes, indicating that this mechanism partially, at least, is
involved in the antidepressant-like effect of limonene on
MS mice.
In case of interventional study with NO precursor and
NOS inhibitor, we showed that coadministration of L-
NAME plus subeffective dose of limonene significantly
potentiated the antidepressant-like effect of limonene at
the subeffective dose. Furthermore, coadministration of
the effective dose of L-arg with the effective dose of limo-
nene significantly mitigated the antidepressant-like effect
of limonene. Our results demonstrated that modulation of
the nitrergic system, partially at least, is involved in the
antidepressant-like effect of limonene on MS mice.
5. Conclusion
In conclusion, we found that limonene exerts antidepressant-
like effects on MS mice by reducing hippocampal nitrite
levels and the neuroimmune response. We found that the
nitrergic system is involved, at least in part, in the
antidepressant-like effect of limonene in MS mice, in which
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coadministration of L-NAME and L-arg enhances and
decreases the effect of limonene, respectively.
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